Drug Search Results
More Filters [+]

HB-0025

Alternative Names: hb-0025, hb 0025, hb0025
Latest Update: 2025-01-03
Latest Update Note: Clinical Trial Update

Product Description

Huabo Biopharm Co., Ltd. is developing HB-0025 as a treatment for solid tumors. (Sourced from: http://www.huabobio.com/en/product.html)

Mechanisms of Action: PD-L1 Inhibitor,VEGF Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Huabo Biopharm Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HB-0025

Countries in Clinic: China, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Endometrial Cancer|Kidney Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HB0025-C-01

P2

Recruiting

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Endometrial Cancer

2025-10-31

HB0025-0101

P2

Recruiting

Kidney Cancer|Renal Cell Carcinoma

2025-01-30

57%

CTR20222862

P2

Not yet recruiting

Kidney Cancer

None

CTR20210604

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title